Innovent Biologics' Efdamrofusp Alfa Marks a Milestone for nAMD Treatment in China Innovent Biologics' recent study shows Efdamrofusp Alfa is the first self-developed medication achieving extended treatment intervals for nAMD in China.

Innovent Biologics' Efdamrofusp Alfa Marks a Milestone for nAMD Treatment in China #China #Suzhou #Innovent_Biologics #Efdamrofusp_Alfa #nAMD

Innovent Biologics Starts Phase 2 Study of Groundbreaking Treatment for Diabetic Macular Edema Innovent Biologics has announced the first patient has been dosed in a Phase 2 clinical trial of efdamrofusp alfa, targeting diabetic macular edema outcomes.

Innovent Biologics Starts Phase 2 Study of Groundbreaking Treatment for Diabetic Macular Edema #China #Suzhou #Innovent_Biologics #Diabetic_Macular_Edema #Efdamrofusp_Alfa

Innovent Presents Groundbreaking Phase 2 Data on Efdamrofusp Alfa at ARVO 2025 Conference Innovent Biologics unveiled promising Phase 2 clinical trial data for Efdamrofusp Alfa, showcasing its potential benefits for nAMD patients at the ARVO 2025 conference.

Innovent Presents Groundbreaking Phase 2 Data on Efdamrofusp Alfa at ARVO 2025 Conference #United_States #Innovent_Biologics #Salt_Lake_City #Efdamrofusp_Alfa #Phase_2_Clinical_Trial